Viridian Therapeutics (VRDN) announced the appointment of Jeff Ajer to its Board of Directors. Ajer most recently served as the Executive Vice President and Chief Commercial Officer at BioMarin Pharmaceutical (BMRN)
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics Enters New $300M Sale Agreement
- Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges
- Viridian Therapeutics: Promising Pipeline and Strategic Progress Support Buy Rating
- Viridian Therapeutics: Promising Market Position and Growth Prospects Justify Buy Rating
- Viridian Therapeutics Reports Strong Progress and Financials
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue